Japanese early-stage life sciences venture capital (VC) firm Catalys Pacific has announced its first healthcare fund with a total corpus of $100 million.
So far, Catalys Pacific has received $80 million in capital commitments for its maiden healthcare fund.
The firm is securing commitments from limited partners including Chugai Pharmaceutical Co., Eisai Co., SoftBank Group, Takeda Pharmaceutical and Celgene Corp.
With the fund, Catalys intends to focus on early-stage investments in life sciences and to also provide healthcare solutions for patients by creating and investing in bioventure companies.